Expertise in
1
conditions

Torsten Liersch

Robert Koch Str. 40, 
Goettingen, NI, DE 
Expertise in
1
conditions
Robert Koch Str. 40, 
Goettingen, NI, DE 
OverviewLocationsClinical Research

Overview

Torsten Liersch practices in Goettingen, Germany. Mr. Liersch is highly rated in 1 condition, according to our data. His top areas of expertise are Colorectal Cancer, Leukocytosis, Metastatic Brain Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

His clinical research consists of co-authoring 53 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Robert Koch Str. 40, Goettingen, NI 37075, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
Enrollment Status: Completed
Publish Date: February 26, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cisplatin, 5-fluorouracil or Capecitabine, Trastuzumab, Pertuzumab
Study Phase: Phase 2
Open, Randomized, Multicenter Phase II Trial With Cetuximab /5-FU/FA/Irinotecan or Cetuximab/5-FU/FA /Irinotecan/Oxaliplatin in K-ras/B-raf Wild Type Patients or With Irinotecan/Oxaliplatin/5-FU/FA With or Without Bevacizumab in K-ras Mutant Patients as Neoadjuvant Treatment in Patients With Non- Resectable Colorectal Liver Metastases.
Open, Randomized, Multicenter Phase II Trial With Cetuximab /5-FU/FA/Irinotecan or Cetuximab/5-FU/FA /Irinotecan/Oxaliplatin in K-ras/B-raf Wild Type Patients or With Irinotecan/Oxaliplatin/5-FU/FA With or Without Bevacizumab in K-ras Mutant Patients as Neoadjuvant Treatment in Patients With Non- Resectable Colorectal Liver Metastases.
Enrollment Status: Unknown
Publish Date: September 11, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

53 Total Publications

Incomplete DPYD haplotype B3 in a patient with locally advanced gastric cancer: Reconsidering the 5-FU dosage strategy.
Incomplete DPYD haplotype B3 in a patient with locally advanced gastric cancer: Reconsidering the 5-FU dosage strategy.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 10, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Liersch's expertise for a condition
ConditionClose
      View All 7 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile